SARS-CoV-2 Sequencing for Variant Surveillance.
SARS-CoV-2 Sequencing for Variant Surveillance.
复制标题
用于变异监测的 SARS-CoV-2 测序。
DOI：
10.1007/978-1-0716-2950-5_16
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Dunne,Jaclyn
中科院分区：
文献类型：
--
作者：
Hirschhorn,JulieWoolworth;Dunne,Jaclyn
在这一章中，描述了严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的下一代病毒基因组测序。SARS-CoV-2病毒的成功测序取决于标本的质量、对整个基因组的充分覆盖以及最新的注释。使用下一代测序进行SARS-CoV-2监测的一些优势是可伸缩性、高通量、成本和全基因组分析。一些缺点可能是昂贵的仪器设备、较大的前期试剂和供应成本、更长的结果产生时间、计算需求和复杂的生物信息学。本章将概述修改后的FDA紧急使用授权程序，用于SARS-CoV-2基因组测序。该程序也被称为仅供研究使用(RUO)版本。
In this chapter, next-generation sequencing of the entire viral genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is described. Successful sequencing of the SARS-CoV-2 virus is dependent upon quality of the specimen, adequate coverage of the entire genome, and up-to-date annotation. Some of the advantages of performing SARS-CoV-2 surveillance using next-generation sequencing are scalability, high-throughput, cost, and full genome analysis. Some of the disadvantages can be expensive instrumentation, large upfront reagent and supply costs, increased time-to-result, computational needs, and complicated bioinformatics. This chapter will provide an overview of a modified FDA Emergency Use Authorization procedure for the genomic sequencing of SARS-CoV-2. The procedure is also referred to as the research use only (RUO) version.